Vera Therapeutics (VERA) Short term Debt (2021 - 2023)

Vera Therapeutics (VERA) has 3 years of Short term Debt data on file, last reported at $3.1 million in Q1 2023.

• For the quarter ending Q1 2023, Short term Debt rose 87.2% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2023 stood at $3.1 million (up 87.2% YoY), and the FY2022 full-year result was $2.8 million, up 172.02% from the prior year.
• Short term Debt for Q1 2023 stood at $3.1 million, up from $2.8 million in the prior quarter.
• Across five years, Short term Debt topped out at $3.1 million in Q1 2023 and bottomed at $994000.0 in Q3 2021.
• The 3-year median for Short term Debt is $1.6 million (2022), against an average of $1.7 million.
• Peak annual rise in Short term Debt reached 172.02% in 2022, while the deepest fall reached 1.01% in 2022.
• A 3-year view of Short term Debt shows it stood at $1.0 million in 2021, then soared by 172.02% to $2.8 million in 2022, then gained by 10.43% to $3.1 million in 2023.
• The last three Short term Debt figures came in at $3.1 million (Q1 2023), $2.8 million (Q4 2022), and $1.0 million (Q3 2022), per Business Quant data.

Peer Comparison